About 2,804 results
Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016
JAMA Psychiatry; Cerda M, et al

Nov 12th, 2019 - This study’s findings suggest that possible increases in the risk for cannabis use disorder among adolescent users and increases in frequent use and cannabis use disorder among adults after legalization of recreational marijuana use may raise public health concerns and warrant ongoing study.

Cannabidiol as a potential treatment for psychosis
Therapeutic Advances in Psychopharmacology; Davies C, et al

Nov 7th, 2019 - Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated wi...

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis
The Lancet Psychiatry; Black, N. et. al.

Oct 27th, 2019 - Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of vario...

Cannabis and cannabinoids for people with multiple sclerosis

Oct 6th, 2019 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess benefit and safety of cannabis‐based medicines, including synthetic, or herbal and plant‐derived cannabinoids, for people with MS.

Self-reported Daily, Weekly, and Monthly Cannabis Use Among Women Before and During Pregnancy
JAMA Network Open; Young-Wolff, K. et. al.

Jul 18th, 2019 - Question Has the frequency of cannabis use among pregnant women in the year before and during pregnancy increased in recent years? Findings In this serial cross-sectional study of 367 403 pregnancies among women in Kaiser Permanente Northern California who were universally screened for self-reported cannabis use as part of standard prenatal care, annual relative rates of daily, weekly, and...

Opioid Medications | FDA

Jun 30th, 2019 - FDA takes actions to combat prescription opioid abuse. Prescription opioids are powerful pain-reducing medications that include prescription oxycodone, hydrocodone and morphine. These medications can help manage pain when prescribed for the right condition and when used properly. But when misused or abused, they can cause serious harm, including addiction, overdose and death

The CBD boom is way ahead of the science

Mar 26th, 2019 - A few months back, a new storefront appeared in my small Oregon town. Its shelves were packed with tinctures, jars of salve, coffee beans, bath bombs — even beard oil. This motley collection shared a single star ingredient: CBD. Produced by the cannabis plant, CBD is the straitlaced cousin of marijuana’s more famous component — the THC that delivers a mind-swirling high. CBD, or cannabidiol,...

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
The Lancet Psychiatry; Forti, M. et. al.

Mar 18th, 2019 - Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder.

Substance-Linked Sex in Heterosexual, Homosexual, and Bisexual Men and Women: An Online, Cross-Sectional “Global Drug Survey” Report
Lawn. W., et al

Mar 1st, 2019 - Introduction Substance use in sexual contexts has received recent attention, but it has mostly been restricted to men who have sex with men and the so-called “chemsex” phenomenon. Aim To explore the use of licit and illicit substances in combination with sex in heterosexual, homosexual, and bisexual men and women; to explore substance-linked sex (SLS) differences across sexual orientation ...

A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C
Powell, D. et. al.

Feb 3rd, 2019 - The hepatitis C virus is responsible for more deaths in the United States than any other infectious disease, and hepatitis C infections have been rising at an alarming rate since 2010. We evaluated the role of the opioid epidemic and, in particular, the 2010 introduction of an abuse-deterrent version of OxyContin. The OxyContin reformulation led some users of the drug to switch to heroin, which...

Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment
Kosten, T. et. al.

Jan 30th, 2019 - The opioid crisis has taken an immense toll in the United States. On average, five lives are lost to an opioid overdose every hour of the day; estimated costs associated with opioid misuse exceed $500 billion annually. Illicit opioid discontinuation is the first step in the treatment of opioid use disorder (OUD), and transition to an opioid agonist may initiate treatment. However, discontinuati...

National Trends in Hospitalizations for Stroke Associated With Infective Endocarditis and Opioid Use Between 1993 and 2015
Omran, S. et. al.

Jan 29th, 2019 - There has been a recent sharp rise in opioid-related deaths in the United States. Intravenous opioid use can lead to infective endocarditis (IE) which can result in stroke. There are scant data on recent trends in this neurological complication of opioid abuse. We hypothesized that increasing opioid abuse has led to a higher incidence of stroke associated with IE and opioid use.

Pharmacotherapies for cannabis dependence
The Cochrane Database of Systematic Reviews;

Jan 27th, 2019 - Background Globally, cannabis use is prevalent and widespread. There are currently no pharmacotherapies approved for treatment of cannabis use disorders. This is an update of a Cochrane Review first published in the Cochrane Library in Issue 12, 2014. Objectives To assess the effectiveness and safety of pharmacotherapies as compared with each other, placebo or no pharmacotherapy (suppor...

Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report
Kroenke, K. et. al.

Jan 24th, 2019 - A national crisis of opioid-related morbidity, mortality, and misuse has led to initiatives to address the appropriate role of opioids to treat pain. Deployment of a guideline from the Centers for Disease Control and Prevention to reduce the risks of opioid therapy has raised substantial clinical and public policy challenges. The agency anticipated implementation challenges and committed to ree...

Association of Childhood Lead Exposure With Adult Personality Traits and Lifelong Mental Health
Reuben, A. et. al.

Jan 22nd, 2019 - Question: Is childhood lead exposure associated with the risk of mental illness or difficult personality traits in adulthood? Findings: In this longitudinal cohort study of 579 New Zealand children followed up for more than 30 years, greater lead exposure in childhood was significantly associated with greater psychopathology across the life course and with difficult personality traits in adulth...

False News of a Cannabis Cancer Cure
Cureus Shi, S. et. al.

Jan 10th, 2019 - Background There is increasing concern among healthcare communities about the misinformation online about using cannabis to cure cancer. We have characterized this online interest in using cannabis as a cancer treatment and the propagation of this information on social media. Materials & methods We compared search activity over time for cannabis and cancer versus standard cancer therap...

FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder

Nov 29th, 2018 - The opioid epidemic is one of the most profound public health crises facing the United States and the current crisis of opioid overdose deaths requires innovative approaches. The agency has already taken significant steps to decrease public exposure to opioids, prevent new cases of opioid use disorder—also known as opioid addiction—and support the treatment of those with the disorder. The FDA r...

Medicinal Cannabis—Potential Drug Interactions

Nov 29th, 2018 - The endocannabinoids system (ECS) has garnered considerable interest as a potential therapeutic target in various carcinomas and cancer-related conditions alongside neurodegenerative diseases. Cannabinoids are implemented in several physiological processes such as appetite stimulation, energy balance, pain modulation and the control of chemotherapy-induced nausea and vomiting (CINV). However, p...

Acetaminophen Toxicity - StatPearls

Nov 13th, 2018 - Acetaminophen (N-acetyl-para-aminophenol, paracetamol, APAP) toxicity is common primarily because the medication is so readily available and there is a perception that it is very safe. More than 60 million Americans consume acetaminophen on a weekly basis. Acetaminophen is used in many products in combination with other preparations, especially with opioids and diphenhydramine. Many people are ...

Regulatory Status of Cannabidiol in the United States: A Perspective
Cannabis and Cannabinoid Research; Corroon, J. et. al.

Oct 17th, 2018 - Cannabidiol (CBD) is 1 of > 100 cannabinoids found in Cannabis sativa L. (Cannabis spp. or Cannabis). Despite its complex and rapidly evolving regulatory status in the United States, projected retail sales of CBD products—hemp, cannabis and pharmaceutical—are as high as $1.9 billion by 2020. CBD products can currently be purchased online, over the counter, and at cannabis-specific dispensaries ...